Clinical Trial

Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment

Study acronym: CHIPOR
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
CHIPOR hypothesis is that the adjunction of platinum HIPEC in first relapsed epithelial ovarian cancer is able to improve the median Overall Survival (OS) by 12 months. In that hypothesis, with alpha risk of 5%, a power beta of 80%, during a 3 years period of inclusion and a 3 years follow-up, the number of patients to include is 404. Taking into account a 10% failure, an overall number of 444 patients is required.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2011-06-17; most recent amendment 2026-05-18.
Status change: Suspended → Active, Not Recruiting 2021-05-03
Status change: Recruiting → Suspended 2020-04-17
Trial Details
NCT Number NCT01376752
Lead Sponsor UNICANCER
Conditions Ovarian Epithelial Cancer Recurrent
Enrollment 415 participants
Start Date 2011-04-26
Primary Completion 2023-01-08 (estimated)
Study Completion 2027-05-14 (estimated)
Updated on ClinicalTrials.gov 2026-05-20